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Abstract
Background: To assess the literature for the impact of iron overload and infusion Iron Chelation
Therapy (ICT) on patients' quality of life (QoL), and the availability of QoL instruments for patients
undergoing infusion ICT. Also, to obtain patients' experiences of having iron overload and receiving
infusion ICT, and experts' clinical opinions about the impact of treatment on patients' lives.
Methods: A search of studies published between 1966 and 2004 was conducted using Medline and
the Health Economic Evaluation Database (HEED). Qualitative results from patient and expert
interviews were analysed. Hand searching of relevant conference abstracts completed the search.
Results: Few studies measuring the impact of ICT with deferoxamine (DFO) on patients QoL
were located (n = 15). QoL domains affected included: depression; fatigue; dyspnoea; physical
functioning; psychological distress; decrease in QoL during hospitalization. One theme in all articles
was that oral ICT should improve QoL. No iron overload or ICT-specific QoL instruments were
located in the articles. Interviews revealed that the impact of ICT on patients with thalassemia,
sickle cell disease, and myelodysplastic syndromes is high.
Conclusion: A limited number of studies assessed the impact of ICT or iron overload on QoL.
All literature suggested a need for easily administered, efficacious and well tolerated oral iron
overload treatments, given the impact of current ICT on adherence. Poor adherence to ICT was
documented to negatively impact survival. Further research is warranted to continue the qualitative
and quantitative study of QoL using validated instruments in patients receiving ICT to further
understanding the issues and improve patients QoL.
Background
Iron overload is caused by an increased absorption of iron
over a long period. Iron overload generally occurs as sec-
ondary to conditions that require repeated blood transfu-
sions. Haemoglobinopathies such as, thalassemia and
Sickle Cell Disease (SCD), and dysfunctional bone mar-
row conditions such as Myelodysplastic Syndromes
(MDS) are all examples of diseases requiring chronic
blood transfusion. If left untreated, iron overload may
result in severe morbidity (such as cardiac disease, diabe-
tes, failure of sexual development, osteoporosis, liver
damage) and early mortality [1]. However, no immediate
iron overload symptoms are present until endocrinopa-
thies and cardiac/organ failure occurs. Given that iron
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overload occurs gradually, it is likely that the impact on
Quality of Life (QoL) will not be noticed until major com-
plications begin to occur in the teens or early twenties for
patients with thalassemia and SCD. Patients with MDS
face the same problem of gradual development of iron
overload with the impact on QoL not noticed until com-
plications begin to occur.
Deferoxamine or desferal (DFO) has until now been con-
sidered the treatment choice for patients with chronic iron
overload due to blood transfusions. When it is adhered to
by patients, it significantly reduces mortality and has an
acceptable safety profile. DFO is taken by infusion, often
mixed by the patients (or their parents) and takes approx-
imately 5–15 minutes to prepare. The preparation is
infused with a thin needle into the arm or abdomen 5
nights per week, for 8 to 12 hours per night [2,3] making
it extremely burdensome for the patient. The site of the
infusion must be rotated. Pumps are available, with a
range in convenience – older pumps tend to be large and
noisy, while newer pumps tend to be smaller and quieter.
Although DFO is regarded as an effective and well toler-
ated drug, local injection site reactions that are generally
not serious but bothersome to patients include bumps,
rashes and bruises, and infections [4,5]. Other side effects
experienced by patients on DFO treatment include: neu-
tropenia; haematological toxicity; shortness of breath;
headaches; and dizziness [6].
Given the inconvenience and side effects of the treatment,
it is likely that iron overload treatment with infusion lim-
its QoL, thereby inhibiting adherence in patients already
limited by thalassemia, SCD or MDS [7-10].
Health Related Quality of Life (HRQoL) is a multidimen-
sional concept that represents the patient's overall percep-
tion of the impact of illness and its treatment. An HRQoL
measure captures at a minimum, physical, psychological
(including emotional and cognitive) and social function-
ing [11]. The measures are seen as methods of capturing
patient's opinions and feelings regarding their disease and
treatment, their perceived need for healthcare and their
preferences for treatment methods and disease outcomes.
A recent study in adults with thalassaemia suggested that
treatment and cultural differences did not have a major
effect on the QoL of patients [12-14]. Pakbaz et al previ-
ously suggested that emotional functioning is one of the
impaired quality of life domains in patients affected by
thalassaemia [15] and a further study showed that thalas-
saemia patients scored low in their emotional functioning
[16].
The objective of this study was to assess the literature for
the impact of iron overload and infusion Iron Chelation
Therapy (ICT) on patients' QoL and to assess the availabil-
ity of QoL instruments that have been used with iron
overload patients.
Methods
The methods used to develop hypotheses for the impact
of infusion ICT on patients with iron overload is detailed
below. It involved a systematic literature review, patient
and expert interviews.
Literature review
We conducted a literature review using electronic data-
bases (Medline and Embase) from 1966 to 2004. The
review used a subject and text word search strategy with
'iron chelation', 'thalassemia', 'sickle cell', and 'myelodys-
plastic syndrome' combined with the terms 'quality of
life', 'burden of illness', 'compliance', 'cost', 'cost benefit',
'cost consequence', 'economic evaluation' and 'utility' as
the main search terms. In addition, Evidence Based Medi-
cine (EMB) reviews were searched including Cochrane
Database of Systematic Reviews (CDSR), American Col-
lege of Physicians Journal Club (ACP), Database of
Abstracts of Reviews of Effects (Dare), and Cochrane Con-
trol Trial Register (CCTR).
Further, an additional search was done of the Health Eco-
nomics Evaluation Database (HEED). For HEED, the
phrases 'iron chelation', 'thalassaemia', 'sickle cell', and
'myelodysplastic syndrome' were used.
The review was restricted to English language studies. To
satisfy the inclusion criteria, studies had to contain articles
that were specific to:
￿ Iron overload and its treatment in thalassemia, SCD or
MDS; or
￿ Iron overload and QoL research.
Any QoL measures that were found to have been used in
the context of patients with iron overload were further
researched in the Patient Reported Outcomes Quality of
Life International Database (PROQOLID), a database that
provides a brief overview of questionnaires used with
patients.
Patient interviews
The interview transcripts of nine patients with iron over-
load were assessed (4 thalassemia, 1 SCD, and 4 MDS) to
determine patients' experiences about the impact of iron
overload and its treatment on their daily lives. In addi-
tion, four patients (2 thalassemia, 1 SCD, and 1 MDS)
participated in a market research study. As part of this
study, the patients were asked to provide an overview of
the impact of iron overload on their lives. We reviewed
the transcripts from these historical interviews in order toHealth and Quality of Life Outcomes 2006, 4:73 http://www.hqlo.com/content/4/1/73
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gain further insight into how infusion ICT impacts
patients' lives.
Expert interviews
Three iron overload experts representing the UK, US and
Italy were interviewed about their observations of the
impact of iron overload and its treatment on patients.
Results
Literature review
At the onset of this review, 539 abstracts were screened, of
which 409 were excluded because of the absence of search
terms from either the title or the abstract. In total, 130 arti-
cles were reviewed; of which only 15 empirical studies had
used validated QoL instruments. Of these, 7 were SCD
studies [17-23], 4 were MDS studies [24-27], and 4 were
thalassemia studies [2,3,28,29]. All of the evaluated stud-
ies focused on the impact of thalassemia, SCD or MDS on
patient QoL rather than the impact of ICT on patient QoL.
However, mention of the impact on QoL of infusion ICT
appears in a number of instances. In one such study, over
50% of patients reported that their activities were often or
very often prevented due to DFO treatment and 65%
reported dislike of DFO. In addition, 56.2% reported that
they would be able to do more things if they did not have
to take DFO [3]. In another study, the degree of discom-
fort associated with DFO treatment was a strong predictor
of negative perception of QoL, with the majority on DFO
reporting QoL to be fair or poor.
A recurring theme with these patients is the impact of
infusion ICT. When these patients were asked what might
improve their QoL, the most frequent response concerned
the improvement of ICT, particularly the development of
an oral drug [28].
Additionally, in another study results indicated that 33%
of patients (17 out of 51) with thalassemia or SCD
recorded a score of zero in every category of the Sickness
Impact Profile (SIP) indicating that some perceived a
reduced QoL during DFO therapy [30].
A significant number of anecdotal reports, as well as infor-
mation derived from clinical experience exist that corrob-
orate our findings regarding the impact of iron overload
or ICT on QoL. All the articles reviewed agreed that the
infusional (characteristic) of Desferal 5–12 h/d five days/
week is a strong impediment of QoL [2,3]. As a corollary,
effective oral ICT should improve the QoL of those with
iron overload [2,3,17-29]. Further, QoL domains reported
as being affected included depression resulting in more
hospital visits [20], fatigue, dyspnoea, physical function-
ing, psychological distress [25], and a general decrease in
QoL during hospitalisation [26].
QoL instruments identified from the search included uni-
dimensional scales such as the Geriatric Depression Scale
(GDS), bi-dimensional scales such as the Hospital Anxiety
and Depression Scale (HADS), and multidimensional
instruments such as the Medical Outcomes Study Short
Form Health Survey 12 items or the 36 items. However,
no iron overload-specific QoL instruments were found.
Results from patient and expert interviews
Since results from the literature review revealed that there
were no iron overload specific QoL instruments, hypoth-
eses were generated based on patient and expert inter-
views in order to develop a disease-specific instrument.
Results revealed that the impact of ICT or iron overload
on QoL is high but will likely differ by the age of the
patient (child, adolescent, young adult, middle aged
adult, elderly adult), the length of time on ICT, and by the
condition (thalassemia, SCD, MDS).
Figure 1 provides an overview of the hypotheses for the
impact of infusion ICT on the QoL of patients with iron
overload. In thalassemia, the impact of infusion ICT on
QoL is most profound, since patients are required to begin
treatment at a very young age (often as young as two or
three years old) and continue throughout their life. As a
result, the impact on the parent can also be quite high
since they have to endure the daily task of inserting a nee-
dle into their child and constant battles with their child in
order to comply with the treatment regimen, which would
then increase parental stress-levels. These battles can carry
on from the youngest age through adolescence and there-
fore may have a negative impact on the parents' relation-
ship with their child and may also cause the child to
become over-dependent on their parent. In addition to
this, the parent may feel tremendous guilt when they 'give
in' to the child's wish not to comply, since they know that
the ICT is required to help their child live longer. In addi-
tion, as the child reaches adolescence or early adulthood
and becomes more in control and responsible for their
own treatment, parents may worry if their child is not ade-
quately adhering to the treatment regimen.
The impact of infusion ICT on all patients is high, but it
appears that the impact may be greatest for adolescents
and young adults (and therefore in thalassemia and SCD),
when being able to socialise with peers. How they are per-
ceived by those peers is of paramount importance. The
unsightly bumps and bruises caused by infusion ICT
appear to most greatly impact adolescents and young
adults, with some reporting that they cannot wear certain
clothes or are too embarrassed to go out. In young adults
and older adults, the impact on work and sex life may also
be quite profound. Given that MDS patients tend to be
elderly, the most likely impact for active MDS patients
would be on evening social life.Health and Quality of Life Outcomes 2006, 4:73 http://www.hqlo.com/content/4/1/73
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When asked about their experiences with infusion ICT,
patients stated that the impact of such therapy included
pain at the injection site (3/9 [33%]), although one
patient reported that the problem was not the pain from
the injection site but rather awareness of the pump.
Patients complained of disrupted sleep because of the
pump (3/9 [33%]), and that ICT interfered with night-
time activities. Further, many patients stated that their sex
lives and relationships were affected by their treatment (4/
9 [44%]), and some stated that the treatment affected
their self-esteem (2/9 [22%]), with some stating that they
chose particular clothes to disguise their pumps (2/9
[22%]).
For all patients, satisfaction with DFO was low, primarily
owing to local injection-site reactions, inconvenience, and
the constraining nature of the therapy. Further, when pre-
sented with a hypothetical oral ICT, patients unanimously
preferred oral ICT to existing treatment.
Discussion
Limited empirical studies have assessed ICT's impact on
QoL in iron overload patients. However, our results from
patient and clinician interviews suggested that the impact
of ICT on iron overload patients is profound. Indeed, our
research also indicated that QoL impact may inhibit pre-
scription of and adherence to infusion ICT. One study
suggested that adherence to ICT is likely to be low given
that there is no immediate threat, symptom or impact
associated with iron overload (i.e. all effects are long
term), a very high impact of infusion ICT on QoL and
apparent low satisfaction with infusion ICT [31]. Another
study also showed significant iron overload in those who
were home transfused indicating poor compliance,
though the link with QoL was not established in that
study [32].
These findings are significant and provide insight into the
impact of iron overload and ICT on patient's daily lives
from both the patients' and clinicians' perspectives. The
Impact of ICT on patients with IO: Results from patient and clinician interviews Figure 1
Impact of ICT on patients with IO: Results from patient and clinician interviews.
Figure 1: Impact of ICT on patients with IO: Results from patient and clinician interviews
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implications of the results suggest that patients are less
likely to adhere or continue their treatment regimens as
recommended by their doctors. The consequences of non-
adherence are significant and may result in severe morbid-
ity (such as cardiac disease, diabetes, failure of sexual
development, osteoporosis, liver damage) and early mor-
tality [7].
Further research is warranted to continue the qualitative
and quantitative study of QoL using validated instru-
ments in patients with thalassemia, SCD, and MDS receiv-
ing ICT, in order to further our understanding of the issues
and so improve patients QoL.
It is important to acknowledge that this literature review
and its findings are based on published English literature
studies which emerged from searching the electronic data-
bases Medline and Embase. Studies were qualitatively dis-
cussed, and there was insufficient data to synthesize the
evidence. Further research could use statistical methods to
explore the net effect of infusion ICT with DFO.
Given that minimal literature was available, we relied on
patient and clinician interviews. Some of the patient inter-
views were historical and the primary purpose of those
interviews was not to assess the QoL of the patients, but
rather to assess their perceptions of current treatments for
iron overload. As a result, in the first instance, we were
required to assess the impact on QoL based on the
answers to questions that were not specific to QoL. Thus,
we may have missed important aspects of life that are
impacted by ICT.
In addition, the clinicians interviewed had experience pri-
marily with iron overload in thalassemia and SCD, rather
than MDS. As a result, we may have over or under-repre-
sented the impact of infusion ICT on MDS patients. We
recommend further qualitative and empirical studies to
assess the impact of infusion ICT and oral ICT in iron
overload patients, using validated QoL instruments to
better ascertain the direct impact.
Nevertheless, even with the aforementioned caveats, our
results indicated that the impact of infusion ICT on QoL
is high. There is a need for easier oral iron chelation ther-
apy that is at least as efficacious and well tolerated in order
to improve QoL, increase prescription and adherence
rates, and ultimately, reduces morbidity and mortality
due to iron overload. Further research should compare
DFO with oral chelation therapy according to such end-
points.
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